The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis
Open accessAbstract
BACKGROUND: The prognostic values of tumor-infiltrating lymphocytes (TILs) and TILs subsets in breast cancer (BC) are uncertain. METHODS: A systematic literature search (MEDLINE, Web of Science, EMBASE, and the Cochrane Library to August 2014) was conducted for studies which met the eligibility criteria. The primary clinical outcome was defined as disease-free survival (DFS), overall survival (OS), and BC-specific survival (BCSS). Random or fixed-effects model was adopted to estimate the summary hazard ratio (HR). RESULTS: Twenty-five published studies comprising 22,964 patients were reviewed. Pooled analysis indicated that TILs were not prognostic markers for DFS and OS in overall population, but related to improved DFS (HR, 0.82; 95% CI, 0.76-0.88) and OS (HR, 0.79; 95% CI, 0.71-0.87) in triple negative breast cancer (TNBC) patients. For TILs subsets, CD8+ lymphocytes were associated with improved DFS (HR, 0.69; 95% CI, 0.56-0.84) and BCSS (HR, 0.78; 95% CI, 0.71-0.86) in overall population, while FOXP3+ lymphocytes were associated with reduced DFS (HR, 1.47; 95% CI, 1.01-2.05) and OS (HR, 1.50; 95% CI, 1.15-1.97). In estrogen receptor (ER) negative patients, CD8+ lymphocytes was also related to better BCSS. In addition, the high density of CD20+, CD3+ or low level of PD-1+ or γδ T lymphocytes indicated increased OS in limited studies. CONCLUSION: TILs and TILs subsets are promising prognostic biomarkers in breast cancer, especially in TNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
REporting recommendations for tumour MARKer prognostic studies (REMARK).
for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602678 · Cited by 1,394
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367
Adams, S., Gray, R. J., Demaria, S., Goldstein, L., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,299
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., Ravoet, M., Le Buanec, H., Sibille, C., Manfouo-Foutsop, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67428 · Cited by 1,070
Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
Ali, H. R., Provenzano, E., Dawson, S.-J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, L., Dunn, J. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu191 · Cited by 774
Muenst, S., Schaerli, A. R., Gao, F., Däster, S., Trella, E., Droeser, R. A., Muraro, M. G., Zajac, P., Zanetti, R., Gillanders, W. E., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2988-5 · Cited by 558
Dieci, M. V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M. C., Delaloge, S., Curigliano, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt556 · Cited by 460
Liu, S., Lachapelle, J., Leung, S., Gao, D., Foulkes, W. D., & Nielsen, T. O. (2012) · Breast Cancer Research · doi:10.1186/bcr3148 · Cited by 436
Muenst, S., Soysal, S. D., Gao, F., Obermann, E. C., Oertli, D., & Gillanders, W. E. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2581-3 · Cited by 334
Ono, M., Tsuda, H., Shimizu, C., Yamamoto, S., Shibata, T., Yamamoto, H., Hirata, T., Yonemori, K., Ando, M., Tamura, K., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1554-7 · Cited by 308
Liu, F., Lang, R., Zhao, J., Zhang, X., Pringle, G. A., Fan, Y., Yin, D., Gu, F., Yao, Z., & Fu, L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1647-3 · Cited by 301
Campbell, M. J., Tonlaar, N. Y., Garwood, E. R., Huo, D., Moore, D. H., Khramtsov, A. I., Au, A., Baehner, F., Chen, Y., Malaka, D. O., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1154-y · Cited by 270
West, N. R., Kost, S. E., Martin, S. D., Milne, K., deLeeuw, R. J., Nelson, B. H., & Watson, P. H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.524 · Cited by 268
The prognostic significance of B lymphocytes in invasive carcinoma of the breast
Mahmoud, S. M. A., Lee, A. H. S., Paish, E. C., Macmillan, R. D., Ellis, I. O., & Green, A. R. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1620-1 · Cited by 261
García-Martínez, E., Gil, G. L., Benito, A. C., González-Billalabeitia, E., Conesa, M. A. V., García, T. G., García-Garre, E., Vicente, V., & de la Peña, F. A. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0488-5 · Cited by 253
Tumor-Infiltrating γδ T Lymphocytes Predict Clinical Outcome in Human Breast Cancer
Ma, C., Zhang, Q., Ye, J., Wang, F., Zhang, Y., Wevers, E., Schwartz, T., Hunborg, P., Varvares, M. A., Hoft, D. F., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201892 · Cited by 214
Andre, F., Dieci, M. V., Dubsky, P., Sotiriou, C., Curigliano, G., Denkert, C., & Loi, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2701 · Cited by 195
An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0987-8 · Cited by 180
Yan, M., Jene, N., Byrne, D., Millar, E. K., O'Toole, S. A., McNeil, C. M., Bates, G. J., Harris, A. L., Banham, A. H., Sutherland, R. L., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2869 · Cited by 180
PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients
Sun, S., Fei, X., Mao, Y., Wang, X., Garfield, D. H., Huang, O., Wang, J., Yuan, F., Sun, L., Yu, Q., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1519-x · Cited by 171
Self-citationLee, S. C., Srivastava, R. M., López-Albaitero, A., Ferrone, S., & Ferris, R. L. (2011) · Immunologic Research · doi:10.1007/s12026-011-8231-0 · Cited by 156 · cited 1×
“On the one hand, some types of immune cells, such as NK cells, cytotoxic T cells, and B cells, were shown to suppress the growth of cancer cells, and a larger amount of immune cells associated with better prognosis [25,34,35].”
BackgroundMohammed, Z. M. A., Going, J. J., Edwards, J., Elsberger, B., Doughty, J., & McMillan, D. C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.347 · Cited by 148
Mohammed, Z. M. A., Going, J. J., Edwards, J., Elsberger, B., & McMillan, D. C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.493 · Cited by 147
Kim, S. T., Jeong, H., Woo, O. H., Seo, J. H., Kim, A., Lee, E. S., Shin, S. W., Kim, Y. H., Kim, J. S., & Park, K. H. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182467d90 · Cited by 146
Takenaka, M., Seki, N., Toh, U., Hattori, S., Kawahara, A., Yamaguchi, T., Koura, K., Takahashi, R., Otsuka, H., Takahashi, H., et al. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.107 · Cited by 146
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.
Flies, D. B., Sandler, B. J., Sznol, M., & Chen, L. (2011) · PubMed Central · Cited by 143
Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas.
Ménard, S., Tomasic, G., Casalini, P., Balsari, A., Pilotti, S., Cascinelli, N., Salvadori, B., COLNAGHI, M. I., & Rilke, F. O. (1997) · PubMed · Cited by 126
Baker, K., Lachapelle, J., Zlobec, I., Bismar, T. A., Terracciano, L., & Foulkes, W. D. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.03846.x · Cited by 121
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
de Graeff, P., Crijns, A. P. G., de Jong, S., Boezen, M., Post, W. J., de Vries, E. G. E., van der Zee, A. G. J., & de Bock, G. H. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605112 · Cited by 115
Hornychová, H., Melichar, B., Tomšová, M., Mergancová, J., Urminská, H., & Ryška, A. (2008) · Cancer Investigation · doi:10.1080/07357900802098165 · Cited by 113
de Kruijf, E. M., van Nes, J. G. H., Sajet, A., Tummers, Q. R. J. G., Putter, H., Osanto, S., Speetjens, F. M., Smit, V. T. H. B. M., Liefers, G., van de Velde, C. J. �., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1844 · Cited by 113
Prognostic impact of FOXP3 expression in triple-negative breast cancer
Lee, S. H., Cho, E. Y., Park, Y. H., Ahn, J. S., & Im, Y. (2012) · Acta Oncologica · doi:10.3109/0284186x.2012.731520 · Cited by 100
Maeda, N., Yoshimura, K., Yamamoto, S., Kuramasu, A., Inoue, M., Suzuki, N., Watanabe, Y., Maeda, Y., Kamei, R., Tsunedomi, R., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3564-2 · Cited by 84
Murri, A. M. A., Hilmy, M., Bell, J., Wilson, C., McNicol, A. M., Lannigan, A., Doughty, J., & McMillan, D. C. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604667 · Cited by 82
Ladoire, S., Arnould, L., Mignot, G., Apétoh, L., Rébé, C., Martin, F., Fumoleau, P., Coudert, B. P., & Ghiringhelli, F. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.261 · Cited by 77
Chen, Z., Chen, X., Zhou, E., Chen, G., Qian, K., Wu, X., Miao, X., & Tang, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095475 · Cited by 75
Self-citationDemir, L., Yigit, S. C., Ellıdokuz, H., Erten, Ç., Somali, I., Küçükzeybek, Y., Alacacıoğlu, A., Çokmert, S., Can, A., Akyol, M., et al. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9602-9 · Cited by 70
Liu, F., Li, Y., Ren, M., Zhang, X., Guo, X., Lang, R., Gu, F., & Fu, L. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2132-3 · Cited by 66
New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK
Hayes, D. F., Ethier, S. P., & Lippman, M. E. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9253-5 · Cited by 54
Aruga (2009) · Oncology Reports · doi:10.3892/or_00000434 · Cited by 44
Kim, S., Lee, A., Lim, W., Park, S., Cho, M. S., Koo, H., Moon, B.-I., & Sung, S. H. (2014) · Journal of Breast Cancer · doi:10.4048/jbc.2014.17.1.8 · Cited by 37
Immunoglobulin Kappa C Predicts Overall Survival in Node-Negative Breast Cancer
Chen, Z., Gerhold‐Ay, A., Gebhard, S., Boehm, D. U., Solbach, C., Lebrecht, A., Battista, M. J., Sicking, I., Cotarelo, C., Cadenas, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044741 · Cited by 37
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., José, V., Fumagalli, D., Brown, D. N., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., et al. (2013) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · Cited by 36
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., José, V., Fumagalli, D., Brown, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V. V., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-s1-05 · Cited by 33
Heys, S. D., Stewart, K. N., McKenzie, E. J., Miller, I. D., Wong, S. Y. C., Sellar, G. C., & Rees, A. J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2190-6 · Cited by 30
Cited by
Hendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 799
Nanda, R., Liu, M. C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., Chien, A. J., Forero-Torres, A., Ellis, E., Han, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6650 · Cited by 710
Hendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000162 · Cited by 709
HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer
Barnes, T. A., & Amir, E. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.220 · Cited by 432
Ogier du Terrail, J., Leopold, A., Joly, C., Béguier, C., Andreux, M., Maussion, C., Schmauch, B., Tramel, E. W., Bendjebbar, E., Zaslavskiy, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02155-w · Cited by 217
Metadata
- Authors
- Mao, Y., Qu, Q., Chen, X., Huang, O., Wu, J., & Shen, K.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-04-13
- Volume
- 11
- Issue
- 4
- Pages
- e0152500
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2340129316
- Cited by
- 275
- References
- 52
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.